Asieris Announced the Completion of Series C Round Financing- to Accelerate the Global Development of Its Innovative Drugs

Shanghai China, March 24th, 2020 – Asieris Pharmaceuticals announced the completion of Series C round funding, raising hundreds of millions of RMB, and a C+ round will soon to be completed. This round of funding was led by Yanyuan Capital, joined by Guozhong Venture Capital, Efung Capital and other investors. Lapam Capital and Kaitai Capital, investors of B round financing, also joined the C round through cooperative funds. The capital raised will be used to support the development of company’s multiple products.